Template:Estrogen dosages for prostate cancer

From HandWiki
Revision as of 19:49, 25 January 2021 by imported>Jworkorg (import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
v · d · e Estrogen dosages for prostate cancer
Route/form Estrogen Dosage Ref(s)
Oral Estradiol 1–2 mg 3x/day [1]
Conjugated estrogens 1.25–2.5 mg 3x/day [2][3]
Ethinylestradiol 0.15–3 mg/day [2][3][4]
Ethinylestradiol sulfonate 1–2 mg 1x/week [5][3][6]
Diethylstilbestrol 1–3 mg/day [2][7]
Dienestrol 5 mg/day [8]
Hexestrol 5 mg/day [8]
Fosfestrol 100–480 mg 1–3x/day [9][10][4]
Chlorotrianisene 12–48 mg/day [2][8][11][4]
Quadrosilan 900 mg/day [8]
Estramustine phosphate 140–1400 mg/day [12]
Transdermal patch Estradiol 2–6x 100 μg/day
Scrotal: 1x 100 μg/day		 [13][14]
[15]
IM or SC injection Estradiol benzoate 1.66 mg 3x/week [16]
Estradiol dipropionate 5 mg 1x/week [16]
Estradiol valerate 10–40 mg 1x/1–2 weeks [17][18]
Estradiol undecylate 100 mg 1x/4 weeks [19][8]
Polyestradiol phosphate Alone: 160–320 mg 1x/4 weeks
With oral EE: 40–80 mg 1x/4 weeks		 [20][19]
[21][8]
Estrone 2–4 mg 2–3x/week [2][22]
IV injection Fosfestrol 300–1200 mg 1–7x/week [9][10][4]
Estramustine phosphate 240–450 mg/day [12][23]
Note: Dosages are not necessarily equivalent.
Template documentation

See also

References

  1. ↑ https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf
  2. ↑ 2.0 2.1 2.2 2.3 2.4 Thomas, John A.; Keenan, Edward J. (6 December 1986). "Estrogens and Antiestrogenic Drugs". Principles of Endocrine Pharmacology. Springer Science & Business Media. pp. 135–165. doi:10.1007/978-1-4684-5036-1_7. ISBN 978-1-4684-5036-1. https://books.google.com/books?id=mTagBQAAQBAJ&pg=PA150. 
  3. ↑ 3.0 3.1 3.2 Oettel, M (1999). "Estrogens and Antiestrogens in the Male". Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Springer Science & Business Media. pp. 505–571. doi:10.1007/978-3-642-60107-1_25. ISBN 978-3-642-60107-1. https://books.google.com/books?id=wBvyCAAAQBAJ&pg=PA538. 
  4. ↑ 4.0 4.1 4.2 4.3 G. Martz (13 March 2013). Die hormonale Therapie maligner Tumoren: Endokrine Behandlungsmethoden des metastasierenden Mamma-, Prostata- und Uterus-Corpuscarcinoms. Springer-Verlag. pp. 51–. ISBN 978-3-642-86282-3. https://books.google.com/books?id=8E-qBgAAQBAJ&pg=PA51. 
  5. ↑ Höfling, G.; Heynemann, H. (2014). "Die orale Östrogentherapie des fortgeschrittenen Prostatakarzinoms — Anlaß für eine Neubewertung?". Der Urologe B 38 (2): 165–170. doi:10.1007/s001310050185. ISSN 0042-1111. 
  6. ↑ Wolfgang Hinkelbein; Kurt Miller; Thomas Wiegel (7 March 2013). Prostatakarzinom — urologische und strahlentherapeutische Aspekte: urologische und strahlentherapeutische Aspekte. Springer-Verlag. pp. 91–. ISBN 978-3-642-60064-7. https://books.google.com/books?id=wdTLBgAAQBAJ&pg=PA91. 
  7. ↑ Aurel Lupulescu (24 October 1990). "Hormones and Hormonotherapy". Hormones and Vitamins in Cancer Treatment. CRC Press. pp. 33–90. ISBN 978-0-8493-5973-6. https://books.google.com/books?id=VddUa-2cp-YC&pg=PA57. 
  8. ↑ 8.0 8.1 8.2 8.3 8.4 8.5 Günther H. Jacobi; Rudolf Hohenfellner (1 December 1982). Prostate Cancer. Williams & Wilkins. p. 223. ISBN 978-0-683-04354-9. https://books.google.com/books?id=4HNrAAAAMAAJ. 
  9. ↑ 9.0 9.1 Sweetman, Sean C., ed (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. p. 2104–2105. ISBN 978-0-85369-840-1. https://www.medicinescomplete.com/mc/martindale/. 
  10. ↑ 10.0 10.1 Franz von Bruchhausen; Gerd Dannhardt; Siegfried Ebel; August W. Frahm; Eberhard Hackenthal; Ulrike Holzgrabe (2 July 2013). Hagers Handbuch der Pharmazeutischen Praxis: Band 8: Stoffe E-O. Springer-Verlag. pp. 301–. ISBN 978-3-642-57994-3. https://books.google.com/books?id=8vSjBgAAQBAJ&pg=PA301. 
  11. ↑ Dao, Thomas L. (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". Antineoplastic and Immunosuppressive Agents. pp. 170–192. doi:10.1007/978-3-642-65806-8_11. ISBN 978-3-642-65806-8. https://books.google.com/books?id=aU_oCAAAQBAJ&pg=PA170. 
  12. ↑ 12.0 12.1 "Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer". Drugs Aging 7 (1): 49–74. July 1995. doi:10.2165/00002512-199507010-00006. PMID 7579781. 
  13. ↑ "Therapy Insight: parenteral estrogen treatment for prostate cancer--a new dawn for an old therapy". Nat Clin Pract Oncol 3 (10): 552–63. October 2006. doi:10.1038/ncponc0602. PMID 17019433. 
  14. ↑ "Transdermal estradiol therapy for advanced prostate cancer--forward to the past?". J. Urol. 169 (5): 1735–7. May 2003. doi:10.1097/01.ju.0000061024.75334.40. PMID 12686820. 
  15. ↑ "Tratamiento del Cáncer de Próstata Avanzado con Estrógenos Transdérmicos Escrotales (ETE)" (in Spanish). Revista Argentina de Urología 70 (4): 231. 2005. ISSN 0325-2531. https://www.sau-net.org/publicaciones/abstracts_70_4.html. 
  16. ↑ 16.0 16.1 "NNR: Products Recently Accepted by the A. M. A. Council on Pharmacy and Chemistry". Journal of the American Pharmaceutical Association (Practical Pharmacy ed.) 10 (11): 692–694. 1949. doi:10.1016/S0095-9561(16)31995-8. ISSN 00959561. 
  17. ↑ https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009402s052lbl.pdf
  18. ↑ Kohli, M.; Alikhan, M. A.; Spencer, H. J.; Carter, G. (2004). "Phase I trial of intramuscular estradiol valerate (I/M-E) in hormone refractory prostate cancer". Journal of Clinical Oncology 22 (14_suppl): 4726–4726. doi:10.1200/jco.2004.22.90140.4726. ISSN 0732-183X. 
  19. ↑ 19.0 19.1 "Parenteral oestrogen in the treatment of prostate cancer: a systematic review". Br. J. Cancer 98 (4): 697–707. February 2008. doi:10.1038/sj.bjc.6604230. PMID 18268497. 
  20. ↑ http://pharmanovia.com/product/estradurin/
  21. ↑ "Estrogens in the treatment of prostate cancer". J. Urol. 154 (6): 1991–8. December 1995. doi:10.1016/s0022-5347(01)66670-9. PMID 7500443. 
  22. ↑ https://www.accessdata.fda.gov/drugsatfda_docs/anda/pre96/85239_Estrone%20Suspension_Prntlbl.pdf
  23. ↑ "Pharmacokinetics and pharmacodynamics of estramustine phosphate". Clin Pharmacokinet 34 (2): 163–72. February 1998. doi:10.2165/00003088-199834020-00004. PMID 9515186. 
Editors can experiment in this template's sandbox (create | mirror) and testcases (create) pages.
Subpages of this template.
Retrieved from "https://handwiki.org/wiki/index.php?title=Template:Estrogen_dosages_for_prostate_cancer&oldid=23653"